Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating on March 27.

Graig Suvannavejh has given his Buy rating due to a combination of factors surrounding Vigil Neuroscience Inc’s promising clinical pipeline and the upcoming key data readouts. The company’s innovative TREM2-based treatments for neurodegenerative diseases, including VGL101 for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and VG-3927 for Alzheimer’s Disease (AD), are approaching critical clinical milestones. Suvannavejh anticipates these events, particularly the IGNITE study’s interim Phase 2 data for VGL101, could potentially drive a significant increase in the company’s stock value.
Moreover, Vigil Neuroscience’s over-enrollment in the IGNITE study due to high physician interest and successful patient awareness initiatives reflects positively on the potential of VGL101. Suvannavejh also notes that the financial results from the fourth quarter are of lesser importance compared to the clinical pipeline updates. The anticipation for the Phase 1 data for VG-3927 and the continued progress of VGL101 through clinical trials underpin the Buy rating and the maintained $13 price target, suggesting substantial upside from the current levels.

Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Terns Pharmaceuticals, and Apellis Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -6.2% and a 44.75% success rate on recommended stocks.

In another report released on March 27, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Vigil Neuroscience Inc (VIGL) Company Description:

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.